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Summary
The susceptibility to infections and the strong Th2
bias observed in neonates are thought to be due to
the immaturity of the dendritic cell (DC) compartment.
We show that neonatal DCs, like their adult counter-
parts, elicit Th1 responses. We also demonstrate that
during potentially harmful systemic inflammation, after
Toll-like receptor (TLR) 9 triggering, neonatal B cells
produce high concentrations of IL-10, preventing op-
timal IL-12 secretion by neonatal DCs and, thus, Th1
priming. Although both CD5+ and CD5− B cell subsets
respond to CpG ODN stimulation, we found that only
CD5+ B cells produce IL-10. Therefore, these results
show the regulatory role of CD5+ B cells on DC activa-
tion in vivo for Th1/Th2 polarization and highlight the
paradoxical effects of TLR triggering in vivo.
Introduction
Adaptive CD4 T helper cell responses can generally be
divided into Th1 and Th2 types based on their cytokine
secretion pattern. Th1 responses are characterized by
IFN-γ secretion and efficiently eliminate intracellular
pathogens and most viral infections, whereas Th2 re-
sponses are characterized by IL-4, IL-5, and IL-13
secretion and efficiently eliminate helminthes and are
involved in allergy response (O’Garra, 1998). Experi-
mental and clinical observations have shown that neo-
nates exhibit less efficient cellular immune responses
to pathogens than adults. Moreover, human and murine
neonatal immune responses are polarized mainly
towards the Th2 type (for review see Adkins et al., 2004;
Siegrist, 2001). These immature or nonprotective im-
mune responses are responsible for the high levels of
morbidity and mortality among neonates and young
children due to infectious diseases, especially in de-
veloping countries (Siegrist, 2001). However, murine
and human neonatal CD4 and CD8 T cells can mount
adult-like responses when stimulated in appropriate
conditions; for example, with appropriate adjuvant
such as Freund’s complete adjuvant (Forsthuber et al.,
1996), with bacterial DNA plasmid encoding microbial
antigen (Martinez et al., 1997), with low doses of virus*Correspondence: rloman@pasteur.fr
2 Present address: Laboratory of Parasitic Disease, National Insti-
tute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.(Sarzotti et al., 1996), or with adult antigen-presenting
cells (APCs) (Ridge et al., 1996).
At least two conditions are required to induce effi-
cient CD4 T cell responses: (1) the maturation of APCs,
i.e., an increase in the number of MHC molecules and
costimulatory molecules on APCs to activate naive T
cells (Banchereau and Steinman, 1998), and (2) the
secretion of Th1- or Th2-driving cytokines, for example,
IL-4 for Th2 cells and IL-12 for Th1 cells (O’Garra, 1998).
Microbial products stimulate APCs to produce cyto-
kines that influence the outcome of Th1 or Th2 re-
sponses. Bacterial DNA (or its synthetic mimic: syn-
thetic oligonucleotides containing unmethylated CpG
motifs, CpG ODN) triggers innate immune responses
through TLR9 and induces the secretion of proinflam-
matory cytokines such as IL-6, IL-12, and TNF-α (Krieg,
2002), in which IL-12 in particular skews immune re-
sponses towards Th1 (Trinchieri, 2003). Early studies
suggest that human or murine neonatal APCs express
lower levels of MHC II than do adult APCs, leading to
poor T cell proliferation or IFN-γ secretion (Lu et al.,
1979; Taylor and Bryson, 1985). Moreover, neonates
would have a very small number of APCs, with a limited
capacity to secrete IL-12 (Goriely et al., 2001; Muthuk-
kumar et al., 2000). It is thus generally accepted that
the immaturity of neonatal APCs limits T cell responses
and is responsible for neonatal immune defects (Adkins
et al., 2004). DCs are the only APCs that can activate
naive T cells (Banchereau and Steinman, 1998). Thus,
we focused on neonatal DCs. In contrast to previous
studies, we recently showed that the spleen of neonatal
mice contains a substantial number of DCs and that
these DCs can secrete IL-12 and type I/II interferons in
vitro and can also induce cytotoxic T lymphocyte (CTL)
responses when adoptively transferred into adult recip-
ients (Dadaglio et al., 2002; Sun et al., 2003). Here, we
investigated the ability of neonatal DCs expressing a
high level of CD11c to prime T helper cells in vivo as
well as their role in T cell polarization in neonates. We
show here that neonatal DCs are as fully competent as
adult DCs in priming and polarizing Th1 responses. In
addition, our findings identify an unexpected regulatory
role of CD5+ B cells in DC activation in vivo for Th1/Th2
polarization through the secretion of IL-10.
Results
The Antigen Presentation and T Cell Stimulatory
Abilities of Neonatal DCs Are Similar
to Those of Adult DCs
We first evaluated the antigen (Ag) presentation and T
cell priming abilities of neonatal DCs in vitro. CD11c+
DCs from 7-day-old neonatal BALB/c mice and from
6- to 10-week-old adult BALB/c mice (Sun et al., 2003)
pulsed with peptide, protein, or bacteria; processed,
and presented with the same efficiency as these Ag to
MHC II restricted, IL-2 secreting T hybridomas. Indeed,
DCs from 7-day-old neonatal mice present the PV1
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468peptide as efficiently as adult DCs to a specific I-Ed- t
irestricted T hybridoma (Figure 1A). Identical results
were obtained with different peptides presented by s
iI-Ad and I-Ab molecules to corresponding hybridomas
(data not shown). Likewise, neonatal DCs also pro- n
acessed protein Ag or live BCG as efficiently as adult
DCs, as shown by MHC II-restricted presentation to u
sspecific T cell hybridomas (Figures 1B and 1C). When
DCs were stimulated by BCG in the absence of T hybri- o
ddoma, no IL-2 was induced (Figure 1C). These results
clearly show that neonatal DCs are fully competent in a
wAg processing and MHC II presentation. Because T hy-
bridomas are only weakly dependent on costimulatory r
wmolecules, we further evaluated the ability of neonatal
DCs pulsed with OVA peptide or protein to stimulate s
enaive OT-II CD4 T cells (Figures 1D and 1E). Neonatal
DCs induced OT-II CD4 T cell proliferation as efficiently i
pas adult DCs. Stimulation with CpG 1826 activated both
adult and neonatal DCs and increased their T cell prim- t
cing ability to a similar extent. Thus, neonatal and adult
DCs have equal antigen presentation and T cell-stimu- L
Tlating abilities.
s
cNeonatal DCs Induce Th1 Responses In Vivo
ain Adult Recipients but Th2 Responses
bin a Neonatal Environment
uBecause neonatal and adult DCs show the same T cell
tpriming ability in vitro, we thus investigated the capac-
tity of neonatal DCs to prime Th1/Th2 responses in vivo.
DCs from 7-day-old mice were purified and loaded with iFigure 1. The Antigen Presentation and T
Cell Stimulatory Abilities of Neonatal DCs
Are Similar to Those of Adult DCs
(A–C) Serial dilutions of neonatal and adult
BALB/c CD11c+ DCs were cultured with or
without antigens, i.e., 10 g/ml PV1 peptide
(A), 40 g/ml MalE protein (B), 3 × 105 CFU
BCG (C), and 105 corresponding IL-2-secre-
ting MHC II-restricted T hybridomas. DCs
cultured with BCG but without hybridomas
were included as a control in (C). The CTL-L
cell line was used to measure the IL-2 con-
centration in the supernatants after 24 hr of
culture.
(D and E) Serial dilutions of neonatal and
adult C57BL/6 CD11c+ DCs were pulsed
with or without 10 g/ml OVA323–339 peptide
(D) or OVA protein (E) in the presence or ab-
sence of 10 g/ml CpG 1826 and then cul-
tured with 104 OT-II CD4 T cells specific for
the OVA323–339 peptide for 3 days. The prolif-
eration of cells is expressed in cpm of incor-
porated [3H]-thymidine.
The results are shown as mean of cpm of
replicates (±SD, indicated by error bars),
corresponding to incorporated thymidine.
Results are representative of at least two
similar experiments.he PV1 peptide, or left unloaded, before being injected
.v. into syngeneic adult mice. Two weeks later, we mea-
ured the IFN-γ and IL-5 released by splenocytes upon
n vitro restimulation with the PV1 peptide. PV1-loaded
eonatal DCs induced a predominant Th1 response in
dults that was characterized by strong IFN-γ prod-
ction and low IL-5 production, whereas no peptide-
pecific cytokine secretion was observed after injection
f unloaded DCs (Figure 2A). No IL-4 was detected un-
er these conditions (data not shown). The same profile
nd level of T cell cytokine secretion were observed
hen PV1-loaded adult DCs were injected into adult
ecipients by the i.p. or the i.v. route (Figure 2A). Next,
e asked whether neonatal DCs would also induce
uch a predominant Th1 response in neonatal recipi-
nts. When PV1-loaded DCs from 7-day-old mice were
.p. injected into age-matched syngeneic recipients, the
eptide-specific T cell response was characterized by
he secretion of large amounts of Th2 (IL-4, IL-5, IL-13)
ytokines in the absence of IFN-γ response (Figure 2B).
ikewise, PV1-loaded adult DCs also primed a strong
h2 response in neonates. The predominant Th2 re-
ponse induced was not due to the intrinsic pattern of
ytokine production by neonatal T cells, as large
mounts of both Th1and Th2 cytokines were produced
y these T cells upon concanavalin A stimulation (Fig-
re 2B, ConA control). The same results were also ob-
ained in C57BL/6 mice (data not shown). We conclude
hat neonatal DCs are fully competent for T cell priming
n vivo and do not intrinsically polarize the immune re-
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469Figure 2. Neonatal DCs Induce Th1 Responses In Vivo in Adult Re-
cipients but Th2 Responses in a Neonatal Environment
Purified neonatal or adult BALB/c CD11c+ DCs (0.5–2 × 105) were
left untreated or loaded with PV1 and injected i.v. or i.p. into adults
(A) or injected i.p. into neonatal syngeneic recipients (B). Two
weeks later, splenocytes from immunized and control mice were
restimulated in vitro with or without 10 g/ml PV1 peptide. Cyto-
kines in the culture supernatants were measured by ELISA for
IFN-γ IL-5 (A and B), IL-4, and IL-13 contents (B). Results are ex-
pressed in ng/ml. In (B), data concerning the splenocyte response
to ConA stimulation are shown as a positive control for cytokine
production. Each point corresponds to an individual mouse. In (A),
statistical analysis with one-way ANOVA is depicted for the IL-5
and IFN-γ secretion between the three groups as indicated, and
p > 0.05 was considered not significant (ns). For (B), the secretion
of IL-4, IL-5, IL-13, and IFN-γ of groups immunized with DCs + PV1
were compared with their respective controls (DCs without PV1),
and the p values were determined by t test (*p < 0.05; **p < 0.01;
***p < 0.001). Levels of IL-5 and IFN-γ cytokines induced by DCs +
PV1 in adult (A) and in neonatal (B) recipients were significantly
different (p < 0.01).sponse to Th2, a feature that is therefore under the con-
trol of the neonatal microenvironment.
In Vitro, but Not In Vivo, Activation by CpG ODN
Enables Neonatal DCs to Induce Th1 Responses
Mature DCs are critical to properly prime T cells (Ban-
chereau and Steinman, 1998). Besides, IL-12 secretedby APCs has been shown to be one of the most impor-
tant Th1 polarization factors (Trinchieri, 2003). Purified
neonatal DCs activated in vitro with CpG ODN produce
a high level of IL-12p70 (1–2 ng/ml) and 50- to 100-
fold more IL-12p40 (Figure 3A). Similar responses were
obtained with different types of CpG ODN (Figure 3A
and see Figure S1A in the Supplemental Data available
with this article online). To further evaluate the capacity
of neonatal DCs to stimulate neonatal Th1 responses,
they were first in vitro instructed with CpG 1826. Under
these conditions, neonatal DCs upregulated MHC II af-
ter 30 min, clearly showing that the activation process
was engaged, although the upregulation of CD86 was
slightly detectable at 1 hr (Figure 3B). Neonatal and
adult DCs cultured with CpG 1826 and loaded with PV1
peptide in vitro induced a Th1 response upon injection
into neonatal recipients (Figure 3C, closed symbols). As
expected, DCs cultured with control ODN (Ctrl 1982)
still primed Th2 responses (Figure 3C, open symbols).
Hence, mature neonatal DCs secreting IL-12 can in-
duce Th1 responses in neonates. We then asked
whether neonatal DCs would also mature in the same
manner in vivo. We injected CpG 1826 into adult or neo-
natal mice. Three hours later, DCs were purified and
loaded with the PV1 peptide. Surprisingly, unlike adult
DCs activated in vivo, neonatal DCs activated in vivo
failed to induce Th1 responses in neonatal recipients
(Figure 4A). Neonatal and adult DCs, purified after ad-
ministration of Ctrl 1982, both induced a Th2 response.
Importantly, CpG 1826 induced upregulation of MHC II,
CD40, CD80, and CD86 molecules on neonatal and
adult DCs with the same efficiency (Figure 4B and data
not shown). In addition, neonatal DCs activated by CpG
1826 in vivo and loaded with a MHC I-restricted CD8+
T cell epitope of lymphocytic choriomeningitis virus
(LCMV NP118–126) induced a stronger CTL response in
neonates, as compared to DCs from mice injected with
Ctrl 1982 (Figure 4C).
Neonatal IL-10 Produced by B Cells after CpG ODN
Administration Limits IL-12 Production by DCs
The fact that in vivo CpG ODN stimulation instructed
adult DCs, but not neonatal DCs, for Th1 priming led
us to analyze the amount of IL-12 secreted in neonates
and adults. We thus injected neonatal and adult BALB/c
mice with CpG 1826, Ctrl 1982, or phosphate-buffered
saline. Three hours later, we analyzed the production of
IL-12 by splenocytes ex vivo. Administration of CpG
1826 (5 mg per kg body weight) induced a strong IL-
12p40 response in adults (2500 pg/ml for 100 g CpG
1826, Figure 5A) but only a weak IL-12 response in neo-
nates (368 pg/ml for 20 g CpG 1826, Figure 5A). IL-
12p70 was not detectable ex vivo after in vivo injection
of CpG ODN (data not shown). Concurrently, CpG 1826
induced noticeable IL-10 secretion in neonates, but not
in adults. Injection of neonates with 100 g of CpG
1826 increased the amount of IL-10, and IL-12 secreted
to the same extent (Figure 5A). The different types of
CpG ODN led to a balanced production of IL-12p40 and
IL-10 in neonates, whereas adult responses were char-
acterized by a predominant IL-12p40 production (Fig-
ure 5B). The same results were obtained in C57BL/6
mice (data not shown), indicating that this phenomenon
is not limited to BALB/c mice.
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470Figure 3. In Vitro Activation by CpG ODN En-
ables Neonatal DCs to Induce Th1 Re-
sponses
(A) 1.4 × 105 purified BALB/c neonatal DCs
were cultured with or without 10 g/ml of A,
B, or C type of CpG ODN for 2 days, and
then IL-12p40 (left y axis) and IL-12p70 (right
y axis) secretions were analyzed by ELISA.
Results are expressed as the mean ± SD of
replicates.
(B) Purified BALB/c CD11c+ neonatal DCs
were analyzed for MHC II and CD86 expres-
sion after in vitro stimulation with 10 g/ml
CpG 1826 for 30, 60, and 120 min.
(C) 5–10 × 104 BALB/c CD11c+ neonatal (cir-
cle symbols) or adult (square symbols) DCs
were activated with CpG 1826 (closed sym-
bols) or Ctrl 1982 (open symbols) with 10 g/
ml PV1 peptide and injected into neonatal
recipients. One to two weeks later, spleno-
cytes were stimulated in vitro with PV1 pep-
tide and cytokines were analyzed by ELISA
as in Figure 2. Each point corresponds to the
responses obtained from individual mice in
at least two independent experiments.IL-10 is a potent anti-inflammatory mediator, which 1
swas first identified as a Th1 inhibitor (Moore et al., 2001)
due to its ability to prevent IL-12 secretion by DCs T
n(Koch et al., 1996). To confirm that IL-10 suppresses IL-
12 production by neonatal DCs, we injected an anti-IL- 1
c10 receptor monoclonal antibody (α-IL-10R Ab [O’Far-
rell et al., 1998]) or a control immunoglobulin (Ctrl Ig, C
BSFR8-B6) into neonates prior to in vivo administration
of CpG 1826. As expected, neonatal DCs secreted l
Tmore IL-12 after CpG ODN in vivo stimulation when IL-
10 signaling was blocked, as compared to DCs from t
smice injected with Ctrl Ig (Figure 5C). DCs do not ap-
pear to be the source of IL-10, as we did not detect IL- t
110 secretion by neonatal DCs after in vivo or in vitro
CpG 1826 stimulation (Figure 5C and data not shown). c
dTherefore, we investigated the source of IL-10 in neo-
natal spleen cells in vitro after CpG ODN stimulation. s
bFACS analysis of IL-10-secreting cells revealed that
B220+ and CD19+ B cells, but not CD3+ T cells or
nCD11b+ myeloid cells, were mainly responsible for IL-
10 production (Figure 6A). This result was confirmed by I
tthe low level of IL-10 production observed with neona-
tal spleen cells from B cell deficient MT mice (Figure t
n6B). Importantly, neonatal spleen cells from MT mice
did not differ from wild-type C57BL/6 mice in the per- p
tcentage of lin− cells, of CD3+ T cells, and of classical
and plasmacytoid CD11c+ DC, but an increase of c
TCD11b+ cells was observed (data not shown). In addi-
tion, stimulation with all types of CpG ODN of neonatal l
eCD19+ B cells induced a strong IL-10 response,
whereas only low levels of IL-10 were produced by a
tadult B cells (Figure 6C). Under these conditions, B
cells produced very low levels of IL-12p40, and IL- a2p70 was not detected (Figure S1B). To definitely as-
ess the role of B cells in IL-10 production in vivo after
LR9 triggering, CD19+ B cells were purified from neo-
atal C57BL/6 neonates or adults injected with CpG
826. In vivo, 3 hr after CpG administration, neonatal B
ells were activated as shown by the upregulation of
D69 (Figure 6D). In these conditions, neonatal CD19+
cells produced large amounts of IL-10, whereas a low
evel of IL-10 was secreted by adult B cells (Figure 6E).
he lack of IL-10 production by B cells from CpG ODN-
reated TLR9-deficient (TLR9−/−) neonatal mice as-
esses the TLR9 dependency of the polyclonal activa-
ion of B cells (Figure 6E). It is noteworthy that CpG
826 similarly stimulated adult and neonatal CD19+ B
ells for in vitro cell proliferation and IgM secretion, in-
icating that the level of TLR9 expression was not re-
ponsible for the difference in IL-10 response observed
etween neonatal and adult B cells (Figure S2).
Furthermore, administration of CpG 1826 to IL-10−/−
eonates leads to the production of a high amount of
L-12 by splenocytes (Figure 6F), confirming the impor-
ant role of IL-10 on IL-12 production in vivo. To assess
he role of B cell-derived IL-10 in vivo, IL-10−/− neo-
ates were transferred with IL-10+/+ neonatal B cells
rior to CpG administration. Under these conditions,
he level of IL-12 induced by CpG ODN was dramati-
ally reduced (Figure 6F). Therefore, although in vivo
LR9 triggering efficiently activates DCs for the upregu-
ation of MHC and costimulatory molecules, it also gen-
rates different cytokine milieus in neonates and in
dults. Thus, IL-10 secretion by neonatal B cells limits
he ability of neonatal DCs to produce IL-12 without
ffecting their capacity to prime CTL.
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471Figure 4. In Vivo Activation by CpG ODN Allows Adult, but Not Neonatal, DCs to Induce Th1 Responses
(A) Neonatal and adult DCs were purified from mice 3 hr after injection of 100 g CpG 1826 (closed symbols) or Ctrl 1982 (open symbols),
then 2–5 × 104 CD11c+ neonatal (circle symbols) or adult (square symbols) DCs were loaded with PV1 peptide and injected into neonatal
recipients. One to two weeks later, splenocytes were stimulated in vitro with PV1 peptide, and cytokines were analyzed by ELISA as in Figure
2. Each point corresponds to the responses obtained from individual mice in at least two independent experiments.
(B) Flow cytometry analysis showing the maturation profile of neonatal and adult DCs after injection of CpG 1826 (neonate, green line; adult,
red line) or Ctrl 1982 (neonate, black line; adult, gray histogram). Three hours after injection, CD11chigh DCs were stained for I-Ad and CD86.
(C) After in vivo activation with CpG 1826 or Ctrl 1982, 1–2 × 105 BALB/c neonatal DCs were loaded with LCMV NP118–126 peptide and injected
into neonatal recipients. Two weeks later, splenocytes were restimulated with LCMV NP118–126 and tested for CTL killing of LCMV NP118–126-
loaded P815 target cells with an effector-to-target ratio of 60:1. Lysis of nonloaded P815 cells was used as a negative control and never
exceeded 4%.In the Absence of IL-10 or of B Cells, In Vivo TLR9
Triggering of Neonatal DCs Allows Th1 Priming
We thus predicted that if neonatal DCs are activated
in vivo by CpG ODN in an IL-10-free or in a B cell defi-
cient environment, their Th1 priming ability would be
restored. When neonatal DCs were activated in vivo by
CpG 1826 in the presence of α-IL-10R antibody, they
induced a Th1-biased response (Figure 7A). In contrast,
DCs from neonates injected with Ctrl Ig still induced a
Th2 response (Figure 7A). To confirm these results, we
activated neonatal DCs in IL-10-deficient (IL-10−/−) B6
mice. IL-10−/− neonatal DCs were stimulated with CpG
ODN in vivo for 3 hr and loaded with a MHC II-restricted
peptide before being injected into C57BL/6 wild-type
neonates. Phenotypic analysis indicated that neonatalDCs were activated by CpG 1826 in vivo with the same
efficiency in IL-10−/− and C57BL/6 wild-type mice (Fig-
ure S3). Again, CpG ODN-activated IL-10−/− neonatal
DCs primed a strong Th1 response when injected into
wild-type neonatal recipients. This response was
marked by high concentrations of IFN-γ and the ab-
sence of IL-4, IL-5, and IL-13 (Figure 7B and data not
shown). To determine the role of IL-10 produced by B
cells in this process, MT neonates were injected with
CpG 1826 to activate DCs. Under these conditions,
DCs were able to prime for Th1 responses when trans-
ferred to neonatal C57BL/6 recipients (Figure 7B). Neo-
natal DCs from untreated IL-10−/− or MT mice still
induced Th2 responses (Figure 7B). These data demon-
strate clearly that neonatal DCs are fully capable of
Immunity
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sFigure 5. After CpG ODN Administration, Neonates Produce a High
Level of IL-10 and a Low Level of IL-12 t
t(A) Adult BALB/c mice were injected with 100 g CpG 1826 (corre-
sponding to 5 mg/kg of mouse weight, square symbols). Neonates u
were injected with PBS or with 100 g Ctrl 1982, CpG 1826, or with t
20 g of CpG 1826 (corresponding to 5 mg/kg, circle symbols). (
Three hours later, 2 × 106 splenocytes were cultured for 72 hr and
DIL-12p40 and IL-10 secretion were tested by ELISA. Each point rep-
mresents an individual mouse.
t(B) 2.5 × 105 neonatal or adult splenocytes were cultured with or
without different types of CpG ODN for 48 hr. IL-12p40 and IL- D
10 secretion was tested by ELISA, and the ratio of IL-12p40/IL-10 i
is shown. w
(C) BALB/c neonates were injected i.p. with 100 g α-IL-10R Ab or
dcontrol Ig (Ctrl Ig) plus 100 g CpG 1826. Three hours later, DCs
M(104) were purified and cultured for 48 hr, and then IL-10 or IL-
r12p40 secretion was analyzed by ELISA. Results are expressed as
the mean ± SD of replicates. i
p
epriming Th1 responses; however, upon TLR9 signaling, T
neonatal B cells secrete IL-10, which decreases IL-12 n
secretion by DCs and thus limits their Th1 priming
ability. p
e
tBoth CD5+ and CD5− Neonatal B Cells Respond
to TLR9 Triggering but Only the CD5+ B Cell s
dSubset Produces IL-10
The question raised by the above results is why neona- n
(tal B cells are much more efficient than adult cells in
producing IL-10 in response to CpG ODN. Early studies t
eshowed that in contrast to the adult spleen, which pos-
sesses only very few B-1 cells, 30% of IgM+ spleen B m
Hcells of 5-day-old mice are Ly-1+ (CD5) B-1 cells (Haya-
kawa et al., 1983) and that B-1 cells can be an impor- m
etant source of IL-10 (O’Garra et al., 1992). Our analysis
of CD5 expression on CD19+ B cells shows that indeed n
tCD5+ B cells represent 30% to 40% of spleen B cells
during the first 2 weeks of life, whereas they account T
tfor less than 5% of B cells in the adult spleen (Figures
8A and 8B). Further analysis of neonatal CD5+ B cells t
ashows that they express a higher level of CD19, IgM,D54, CD11a, CD44, and TSLP-R as compared to CD5−
cells (data not shown) but do not express CD11b (Fig-
re 8B). They are also positive for MHC II, CD1d, CD40,
nd CD43 (data not shown). We then compared the ca-
acity of CD5+ and CD5− B cells to respond to TLR9
ignaling. In response to CpG ODN, both B cell subsets
roliferated with similar efficiency (Figure 8C), whereas
nly CD5+ B cells produced a high level of IL-10 (Figure
D). These results show that CpG ODN induces a dif-
erent activation program in CD5+ and CD5− B cell sub-
ets and that only CD5+ B cells are responsible for the
L-10-mediated control of DC activation following
LR9 triggering.
iscussion
n this report, we have analyzed the in vitro and in vivo
cell priming functions of neonatal DCs. Our results
learly show that neonatal DCs have identical antigen-
resenting and T cell-priming abilities as adult DCs and
re capable of inducing Th1 responses in an adult mi-
roenvironment. Although the development of naive T
ells to Th1 or Th2 cells is still not completely under-
tood, it is clear that the cytokine milieu surrounding
he emerging T cell responses is mainly responsible for
he Th1 or Th2 polarization. Other factors also contrib-
te to this differentiation, such as signal strength or an-
igen dose (Hosken et al., 1995), genetic background
Guler et al., 1996), the nature of different subsets of
Cs (Maldonado-Lopez et al., 1999), or costimulatory
olecules (Kuchroo et al., 1995). However, none of
hese factors explains why the Th1 priming ability of
Cs is defective in neonatal recipients but is effective
n adults. In contrast to the study of Dakic et al. (2004),
e show that neonatal DCs present antigens to T hybri-
omas or CD4+ T cells as efficiently as adult DCs.
oreover, neonatal DCs induce Th1 responses in adult
ecipients, indicating that neonatal DCs express a sim-
lar level of MHC II and costimulatory molecules and
ropose similar strength of signal to prime T cells. How-
ver, both BALB/c and C57BL/6 neonatal DCs induced
h2 responses in neonatal recipients, showing this is
ot a mouse-strain-limited default.
Adkins et al. (2002) showed that neonatal T cells
rimed in an adult microenvironment still show a prefer-
ntial Th2 expansion over Th1 responses, suggesting
hat neonatal T cells require a different threshold of
timulation to be polarized. Recently, Li et al. (2004)
emonstrated further that in contrast to adult Th1 cells,
eonatal Th1 cells express an atypical receptor for IL-4
IL-13Rα/IL-4Rα) that induces apoptosis of Th1 cells af-
er IL-4 stimulation. These studies indicate that differ-
nces exist between neonatal and adult T cells that
ay influence their capacity to develop Th1 responses.
owever, these studies did not address the issue of DC
aturation in these responses, and we show here that
fficient neonatal Th1 responses can be elicited when
eonatal DCs are appropriately activated. The matura-
ion or activation of DCs, which are required to initiate
cell immune responses, can be induced by inflamma-
ory signals (upon infection) or physical stress (disrup-
ion of cell-cell contact, purification procedure, or in vivo
doptive transfer) (Bousso and Robey, 2003; Pierre et
B Cells Regulate Neonatal DC Activation
473Figure 6. Neonatal B Cells Produce IL-10 in
Response to CpG ODN and Limit IL-12 Pro-
duction by DCs
(A) Spleen cells from neonates were stim-
ulated in vitro with 10 g/ml CpG ODN for 72
hr, then IL-10-secreting cells were analyzed
by FACS for B220-, CD19-, CD3-, or CD11b-
positive cells. The percentage of IL-10-
secreting cells is indicated in the right quad-
rants.
(B) Spleen cells from C57BL/6 and MT neo-
nates and from C57BL/6 adults were stim-
ulated in vitro with CpG 1826 and analyzed
for IL-10 production.
(C) 106 neonatal or adult C57BL/6 CD19+ B
cells were purified and cultured with 10
g/ml of the different types of CpG ODN for
48 hr, and then IL-10 secretion was analyzed.
Results are expressed as the mean ± SD of
replicates.
(D) C57BL/6 CD19+ B cells from PBS (grey
histogram) and CpG 1826-injected (bold line)
neonates were analyzed for CD69 expres-
sion 3 hr after injection.
(E) TLR9−/− or wild-type C57BL/6 neonates
and adults were injected with 100 g CpG
1826 or Ctrl 1982, and 3 hr later CD19+ B
cells were purified and analyzed for IL-10
production. The IL-10 secretion is also
shown for the spleen cell fraction depleted
of B cells (CD19−). Results are expressed as
the mean ± SD of replicates.
(F) IL-10−/− neonates were transferred with
2 × 106 neonatal CD19+ B cells from C57BL/6
(IL-10+/+) or left untreated prior to injection of
100 g CpG 1826. Three hours later, spleno-
cytes from these neonatal mice were cul-
tured for 48 hr and analyzed for IL-12p40
secretion.al., 1997). These signals may induce different degrees
of DC maturation in terms of phenotypical changes and
cytokine secretion patterns. In this regard, under our
experimental conditions, the purification procedure
certainly induced the maturation of DCs without re-
markable cytokine secretion but with enough to prime
Th1 responses when they were transferred into adult
recipients. However, to prime Th1 responses in neo-
nates, full maturation of DCs with stronger IL-12 secre-
tion seems necessary. Therefore, our results show that
the key event in neonatal Th1/Th2 polarization is the
appropriate activation of DCs.
Strikingly, our results highlight that after TLR9 signal-
ing, B cells tightly control the activation of neonatal
DCs for Th1 priming through IL-10. In the conventional
sequence of events required to stimulate adaptive im-
mune responses, DCs first activate CD4+ T cells, which
may further help B cells for antibody production. DCs
may also regulate B responses directly. Some studies
demonstrate that with the collaboration of T cells, DCs
regulate the activation and proliferation of B cells by
the secretion of IL-6 and IL-12 (Dubois et al., 1998,
1997). It has also been shown that human plasmacytoid
DCs regulate B cell activation by IFN-α secretion duringviral infection (Jego et al., 2003). It has also been sug-
gested that B cells may regulate activation of T cells
by steady-state DCs (Moulin et al., 2000). However, to
initiate T cell activation, DCs need to also be activated
by microbial products through the triggering of sensor
molecules such as TLRs. Here, we show that after TLR9
signaling, B cells act upstream on DCs to regulate the
T cell immune response. This TLR signaling triggers
both B cell and DC activation, but the innate B cell re-
sponse prevails over DC functions. This takes place in
early life and may represent a developmentally regu-
lated mechanism.
Different cells are reported to secrete IL-10, like ma-
crophages, CD25+ T regulatory cells (Shevach, 2002),
or Kupffer cells during sepsis (Emmanuilidis et al.,
2001). There is little information about the regulatory
CD25+ T cells during the neonatal period. Thymectomy
of BALB/c mice at day 3 of life demonstrates that elimi-
nation of CD25+ T cells in the thymus at this period
induces autoimmune gastritis 3 to 4 weeks later (Suri-
Payer et al., 1998), indicating that CD25+ T cells may
work early in life. However, their regulatory functions
during the neonatal period need to be further docu-
mented. Importantly, these cells are not involved during
Immunity
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tFigure 7. In the Absence of IL-10 or of B cells, In Vivo TLR9 Trigger-
ping of Neonatal DCs Allows Th1 Priming
i(A) BALB/c neonates were injected i.p. with 100 g α-IL-10R Ab or
control Ig (Ctrl Ig) plus 100 g CpG 1826. Three hours later, DCs c
(105) were purified, loaded with peptide, and injected into BALB/c p
neonates. One to two weeks later, splenocytes were stimulated in i
vitro as in Figure 2. Each point represents an individual mouse. The l
linear regression line of Th1 cytokine (IFN-γ) versus Th2 cytokines
o(IL-5 and IL-13) detected by ELISA is shown.
s(B) DCs from IL-10−/− (n = 13) or from MT (n = 11) neonates in-
jected with CpG 1826 were loaded with peptide Ag85A241–260 or
MalE221–235, and 1.4–10 × 104 DCs were transferred into C57BL/6 d
wild-type neonatal recipients. As a control, nonactivated DCs from n
IL-10−/− (n = 4) or MT (n = 5) neonates loaded with peptide were u
injected into C57BL/6 neonates. Th1/Th2 cytokines were deter-
dmined as in (A).
r
E
T
the cytokine storm induced by CpG ODN. Indeed, after c
TLR9 triggering, we identified B cells as the main t
source of IL-10, but not T cells or myeloid cells. The f
data from MT splenocytes confirm this observation. a
The strong production of IL-10 by neonatal, but not I
adult, B cells in response to CpG ODN is due to the f
fact that only CD5+ B cells are able to secrete this cy-
tokine in these conditions and that the CD5+ B cell sub- E
set is more abundant in early life. Indeed, the DC:B cell
Mratio in the spleen is similar (i.e., about 1:25–30) in early
Blife as well as in adults (Dadaglio et al., 2002); in con-
J
trast the DC:CD5+ B cell ratio is 1:10 and 1:1 in the 1
neonatal and adult spleen, respectively. We have pre- c
fviously shown that B cells and DCs are the first dif-
aferentiated cell types to colonize the spleen after birth
p(Sun et al., 2003). CD5+ B cells are believed to develop
g
mainly from fetal liver (Herzenberg, 2000). However, the a
neonatal liver, as well as the spleen, is still a source of n
aB cells, whereas the contribution of the bone marrow
oto the B cell compartment is developing (Hardy, 2003).
5The high number of CD5+ B cells observed in the spleen
for the first 2 weeks of life much likely reflects this C
hematopoietic scheme. Regarding other B cell subsets, C
nno marginal zone B cells were found during the firsteek of life (data not shown). It is important to note that
LR9 signaling triggers a different activation program in
D5+ and CD5− neonatal B cells. Both B cell subsets
roliferate and secrete IgM, but only the CD5+ B cell
ubset is able to produce IL-10. Therefore, differences
n subpopulations of B cells early in life are responsible
or DCs regulation after TLR9 signaling. Whether such a
egulation mechanism takes place in the adult immune
ystem remains to be determined; however, it is likely
hat the encounter of these two cell types may occur.
The regulatory role of neonatal IL-10 does not impair
he capacity of DCs to prime T cells but restrains their
apacity to secrete IL-12 and to mount Th1 responses.
herefore, it is possible that this regulation process is
mportant to limit the development of an exacerbated
h1 response. Some studies demonstrate that IL-10
ecretion by B cells plays a critical role in controlling
ifferent autoimmune diseases like experimental auto-
mmune encephalomyelitis or arthritis (Fillatreau et al.,
002; Mauri et al., 2003). Of note, administration of CpG
DN in combination with α-IL-10R Ab to neonates or
f CpG ODN alone to an IL-10−/− neonate was lethal
ithin 24–48 hr (data not shown). Preliminary observa-
ions indicate further that CpG ODN induces some apo-
tosis and an important extravasation of lymphocytes
n different organs of IL-10−/− neonates that is not the
ase in wild-type neonates (our unpublished data). This
henomenon is observed mainly in the lungs, but also
n the liver and spleen. However, CpG ODN was not
ethal in MT neonatal mice, indicating that the control
f this lethal inflammation by IL-10 may be compen-
ated by another mechanism in MT neonates.
Our results elucidate an important mechanism un-
erlying the inefficient induction of Th1 responses in
eonatal mice and demonstrate that B cells have a reg-
latory role over DCs functions. These results also un-
erline that when triggering TLR in vivo, all the different
esponding cell types should be taken into account.
arly release of IL-10 in neonatal CD5+ B cells limits the
h1 priming ability of neonatal DCs by reducing their
apacity to produce IL-12. This opens up new perspec-
ives for the treatment of infections during early life and
or the prevention of allergic diseases. Moreover, the
bsence or the poor stimulation of neonatal B cells for
L-10 production may represent an important criterion
or the design of future vaccines for neonates.
xperimental Procedures
ice
ALB/c and C57BL/6 adult mice were purchased originally from
anvier (Le Genest St. Isle, France). C57BL/6-IL-10-deficient (IL-
0−/−; obtained from A. Bandeira, Institut Pasteur, Paris, France), B
ell-deficient C57BL/6 (MT), TLR9-deficient (TLR9−/−; obtained
rom P. Vieira, Institut Pasteur, Paris, France), and OT-II mice, all on
C57BL/6 background, were bred in our animal facilities. For pups,
regnant females were bred and housed on-site in specific patho-
en-free conditions. Neonatal mice are defined as 7 days old and
dult mice as 6–10 weeks old. Spleen cells from MT and IL-10−/−
eonatal mice did not differ from C57BL/6 neonatal mice (Sun et
l., 2003) in composition of plasmacytoid DC (B220+ CD11clow) and
f the different CD11chigh DC subsets, i.e., 30%–35% of CD8+ DC,
0%–60% of CD8−CD4− DC, and about 10% of CD4+ DC.
ulture Medium and Reagents
omplete medium (CM) consisted of RPMI-1640 containing L-ala-
yl-L-glutamine dipeptide supplemented with 5%–10% fetal calf
B Cells Regulate Neonatal DC Activation
475Figure 8. CD5+, but Not CD5−, Neonatal B
Cells Are Responsible for IL-10 Production
in Response to CpG 1826
(A and B) Spleen B cells of C57BL/6 mice
were analyzed for CD5 expression from birth
to adulthood. In (B), CD19+ gated cells of
adult (top) or neonatal (bottom) spleen were
also analyzed for CD11b expression.
(C and D) Purified CD19+CD5+ and
CD19+CD5− cells from neonatal C57BL/6
mice were cultured with medium alone or
with 10 g/ml of CpG 1826. After 48 hr, cell
proliferation (C) and IL-10 content (D) in the
supernatant were determined. Results are
representative of four similar experiments.serum (FCS, ICN Biomedicals, Inc.), 5 × 10−5 M of 2-ME (Sigma),
and antibiotics (penicillin 100 U/ml, streptomycin 100 g/ml,
GIBCO BRL). In some experiments, cells were cultured in HL-1 se-
rum-free medium (Bio Whittaker). Type A, B, and C of CpG ODN
(CpG 1826, 5#-TCCATGACGTTCCTGACGTT-3#; CpG 2006, 5#-TCG
TCGTTTTGTCGTTTTGTCGTT-3#; CpG 2216, 5#-GGGGGACGATC
GTCGGGGGG-3#; CpG 2395, 5#-TCGTCGTTTTCGGCGCGCG
CCG-3#) and control ODN (Ctrl 1982, 5#-TCCAGGACTTCTCTCAG
GTT-3#; Ctrl A, 5#-GGGGGAGCATGCTGCGGGGG-3#) (Klinman et
al., 1996; Vollmer et al., 2004) were synthesized by PROLIGO. Bold-
face nucleotides correspond to phosphorothioate backbone. The
following peptides were used: KLFAVWKITYKDTV (PV1), QDA
YNAGGGHNGVFDFPDSG (Ag85A241–260), ETAMTINGPWAWSNI
(MalE221–235), ISQAVHAAHAEINEAGR (OVA323–339), and RPQASG
VYM (LCMV NP118–126). All synthetic peptides were purchased from
Neosystem. Purified E. coli MalE protein provided by J.M. Clement
(Institut Pasteur, Paris, France). M. bovis BCG 1173P2 was a kind
gift from G. Marchal (Institut Pasteur, Paris, France).
Cell Purification and FACS Analysis
Spleens were treated with collagenase D and DNase I (Roche Mo-
lecular Biochemicals) and then dissociated in Ca2+-free medium in
the presence of EDTA. DCs were positively selected by anti-CD11c
MicroBeads (N418), and B cells were selected with anti-CD19
MicroBeads (1D3) (Miltenyi Biotec) and AutoMACs (Miltenyi Bio-
tec). The purification procedure used for DCs led to the selection
of classical CD11c+ DCs, but not of plasmacytoid DCs. In some
experiments, CD19+ cells were further stained by phycoerythrin
(PE)-conjugated anti-CD5 antibody (53–7.3) and sorted as CD5+
and CD5− B cell subsets by flow cytometry on a FACSTARplus (BD).
For OT-II CD4 T cell purification, lymph node CD4 T cells from OT-
II mice were enriched by immunomagnetic beads (Miltenyi Biotec)
of anti-CD45R/B220 (RA3-6B2), anti-CD8α (53-6.7), anti-CD11b
(M1/70.15.11.5), anti-CD11c (N418), and anti-CD19 (1D3). Purity of
cells was checked by flow cytometry on a FACSCalibur (BD Biosci-
ences) with allophycocyanin (APC) or PE-conjugated anti-CD11c
(HL3) for DCs, APC-conjugated anti-CD19 (1D3) for B cells, PE-
conjugated anti-CD4 (RM4-5), and fluorescein isothiocyanate
(FITC) conjugated CD90.2 (53-2.1) for CD4+ T cells. Purity was usu-ally >95% for adult DCs, T cells, and neonatal B cells and 85%–
95% for neonatal DCs. DC maturation or B cell activation was
assessed with FITC conjugated anti-I-Ab (25-9-17), anti-I-Ad (AMS-
32.1), anti-CD40 (HM40-3), anti-CD80 (16-10A1), anti-CD69 (HI.2F),
or anti-CD86 (GL1) mAbs. All mAbs were from BD Pharmingen.
Antigen Presentation Assay
All T hybridomas were generated in our laboratory. The 45G10 T
cell hybridoma is specific for the PV1 peptide and is I-Ed restricted,
the FBCD1 T cell hybridoma is specific for MalE221–235 and is I-Ad
restricted, and the CG11 T cell hybridoma is specific for the BCG
Ag85A241–260 and is I-Ed restricted. For antigen presentation to T
cell hybridomas, serial dilutions of purified neonatal or adult
BALB/c CD11c+ DCs were pulsed with peptides, proteins, or BCG
and then incubated with the corresponding T cell hybridoma for 24
hr. The culture supernatants were frozen for at least 2 hr at −80°C,
thawed, tested for IL-2 content by using 104 cells/well of the IL-2
dependent CTL-L cell line, and cultured for 3 days. For T cell prim-
ing of OT-II CD4 T cells, serial dilutions of purified neonatal or adult
C57BL/6 DCs were incubated with OVA323–339 alone, or with
OVA323–339 or OVA protein and 10 g/ml CpG ODN for 1 hr, then
incubated with 104 OT-II CD4 T cells for 3 days. For cell proliferation
analysis, cells were pulsed with [3H]-thymidine (ICN Biomedicals,
Inc.) for the last 6–18 hr of culture and harvested by an automated
cell harvester (Skatron), and scintillation was counted. In all experi-
ments, each point was done in at least triplicate. Results are ex-
pressed as the mean ± SD of cpm. No proliferation of OT II cells
cultured with OVA protein alone was detected.
Immunization Procedure
Purified neonatal or adult DCs were loaded or not with appropriate
peptide (5 g/105 cells or 100 g/ml) in RPMI-1640 medium with
1%–2% mouse serum for 30–60 min at 37°C. In some experiments,
DCs were activated in vivo by injection of 100 g CpG ODN or Ctrl
ODN 3 hr before peptide loading, or in vitro with 10 g/ml CpG
ODN, then DCs were loaded with peptides. For blocking IL-10 sig-
nal, 100 g anti-IL-10 receptor mAb (α-IL-10R, clone 1B1.3a, BD
Pharmingen) or control immunoglobulin (Ctrl Ig, clone SFR8-B6
[Radka et al., 1982]) was injected 15 min before CpG ODN injection.
Immunity
476After peptide loading, 2–20 × 104 DCs were then washed twice with g
PBS and injected into adult (i.v. or i.p.) or into 7-day-old (i.p.) synge- 4
neic mice. One to two weeks after immunization, splenocytes were A
isolated for cytotoxicity assay or cytokine secretion assay. The DC a
number used for injection influenced the intensity of the T response
B
measured but did not modify the cytokine profile of the response.
c
BCytotoxicity Assay
bTwo weeks after immunization, splenocytes were isolated and re-
stimulated in vitro with 0.1 g/ml LCMV NP118–126 in the presence D
of syngeneic irradiated naive splenocytes for 5 days. The cytotoxic (
activity was determined in a 4 hr, in vitro 51Cr release assay with s
P815 tumor cells incubated or not with LCMV NP118–126 peptide as D
the target cells. The percentage of specific lysis was calculated as S
100× ([experimental release – spontaneous release]/[maximal re- s
lease – spontaneous release]). Results are expressed as % of
Dspecific lysis (percent of lysis in the presence of peptide − percent
Clysis in the absence of peptide).
e
cCytokine Analyses
DFor cytokine secretion, splenocytes from immune mice were re-
stimulated with the appropriate peptide for 72 to 96 hr and culture B
supernatants were tested for Th1 and Th2 cytokines. 106 spleno- d
cytes were cultured with 5 × 105 irradiated syngeneic adult spleno- n
cytes as feeders in CM with or without 10 g/ml of the correspond- E
ing peptide. 72–96 hr later, supernatants were harvested and m
cytokines were detected. Results are expressed in ng/ml and cor- H
respond to the cytokine produced in the presence of peptide after h
subtraction of cytokine produced in the absence of peptide. In the
Fabsence of peptide stimulation, only adult immune spleen cells
tproduced IFN-γ cytokine but at levels between 10%–30% of the
1response observed in the presence of peptide. Identical responses
Fwere observed in the presence or in the absence of irradiated syn-
ageneic adult splenocytes. For in vitro cytokine secretion, whole
splenocytes, purified DCs, and B cells were isolated and cultured G
with CpG ODN in serum-free HL-1 medium for 48 hr. DCs were m
cultured in the presence of IL-4 and GM-CSF. For ex vivo cytokine s
secretion, mice were injected with 100 g CpG ODN or Ctrl ODN n
then, 3 hr later, cells were directly cultured for 48–72 hr. IL-4, IL-5,
GIL-10, IL-12p40, IL-12p70, and IFN-γ were measured by standard
Dsandwich ELISA with appropriate Ab pairs (all from BD Phar-
Lmingen). IL-13 was captured by purified anti-IL-13 mAb (clone
e38213.11; R&D Systems) and detected by biotinylated IL-13 Ab
H(R&D Systems).
C
IL-10 Secretion Assay H
Characterization of IL-10-secreting cells was performed by stimu- (
lating total spleen cells with CpG ODN for 1–3 days. Flow cytometry a
analysis of IL-10-producing cells was performed with an IL-10 H
Secretion Assay Detection kit (Miltenyi Biotec) together with FITC-
I
conjugated anti-B220, anti-CD19 (1D3), anti-CD3 (17A2), or anti-
HCD11b (M1/70) mAbs (BD Pharmingen).
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